This three day event will discuss aspects of Malaria control, infection and treatment in an informal academic setting. This year there are three main topics for discussion:

1. Vector Control: Research, Economics and Policy
2. Immunology and Vaccination
3. Malaria Drug Development and Resistance Control

With plenty of opportunity for networking and debate, this informal international meeting will bring you up to date with current research and thinking regarding Malaria.

This event has CPD accreditation.

www.regonline.co.uk/Malaria2014
Contents

Program Outline ........................................................................................................................................ 5

Day 1: Vector Control: Research, Economics and Policy ........................................................................ 5
Session Chair: Miss Giulia Boselli, Global Health Specialist- Consultant, UK .......................................... 5

Day 2: Immunology and Vaccination ........................................................................................................ 5
Session Chair: ........................................................................................................................................... 5

Day 3: Drug Development and Resistance Control .................................................................................. 5
Morning Session Chair: Dr Glenn McConkey, Univeristy of Leeds, UK ..................................................... 5
Afternoon Session Chair: .......................................................................................................................... 5

Agenda ....................................................................................................................................................... 6

Vector Control: Research, Economics and Policy .................................................................................... 6
Introduction by the Chair .......................................................................................................................... 6
Possible new controlling measures for the pyrethroid-resistant malaria vectors ........................................ 6
Malaria control in coastal areas - special research and policy needs .......................................................... 6
MALE FERTILITY FOLLOWING OCCUPATIONAL EXPOSURE TO DDT .................................................. 6
Enantioselective pharmacologic and toxicologic profiles of 8-aminoquinoline antimalarials ....................... 6
Education in the successful elimination of malaria in Palestine begun 90 years ago .................................... 6

Immunology and Vaccination .................................................................................................................... 7
Introduction by the Chair .......................................................................................................................... 7
Citrulline: A novel therapeutic for the cerebral malaria .............................................................................. 7
Prospects for Preganancy-Associated Malaria Vaccination Predicated on Antibody-Mediated Immunity .......................................................... 7
Etiology and treatment of cerebral malaria ................................................................................................ 7
Dendritic cells during malaria infection ..................................................................................................... 7
TAntibody longevity to malaria vaccine candidate antigens in immuno-epidemiology studies ..................... 7
Platelets do not kill blood-stage Plasmodium parasites but function in experimental cerebral malaria pathogenesis .......................................................................................................................... 7

Drug Development and Resistance Control ............................................................................................ 8
Introduction by session Chair .................................................................................................................... 8
Malaria Drug Discovery: From genome to drug lead .................................................................................. 8
Natural products as a source of new drugs and/or herbal treatments for malaria ........................................ 8
Fast tracking antimalarial drug discovery through repositioning .................................................................. 8
12:30 – 12:40 DISCOVERY OF PROMISING NOVEL ANTIMALARIAL THIENOPYRIMIDINONE DERIVATIVES .......................................................... 8
12:40 – 12:50 Khaya grandifoliola: POTENTIAL SOURCE OF ANTI-MALARIAL DRUG .......................................................... 8
Introduction by session Chair .................................................................................................................... 8
Development of enantiomerically pure aminoalcohol quinoline derivatives to improve their antimalarial efficiency and assessment of their activity against Plasmodium falciparum in combination with dihydroartemisinin .......................................................... 8
Artemether Loaded Nanoparticles: Development using Quality by Design approach, evaluation of antimalarial efficacy and uptake specifically by malaria-infected erythrocytes .......................................................................................................................... 8
Antimalarials that improve the immune response ...................................................................................... 8
NEW ANTIMALARIAL DRUG LEADS AND MOLECULAR TARGETS IDENTIFIED THROUGH MULTIDIRECTIONAL SCREENING AND DRUG DISCOVERY APPROACH ................................................................. 8
Malaria control: the nutraceutical potential of natural cocoa powder ................................................................. 8
Treating malaria at the expense of public health? ........................................................................................................ 8
About the Speakers ................................................................................................................................................... 9
Day 1 ....................................................................................................................................................................... 9
Hitoshi Kawada ........................................................................................................................................................ 9
Ranjan Ramasamy .................................................................................................................................................... 9
Anton Alexander ...................................................................................................................................................... 9
Day 2 ....................................................................................................................................................................... 9
Andrew Taylor-Robinson, ...................................................................................................................................... 9
Jacob Golenser ........................................................................................................................................................ 9
Pierre Guermonprez .................................................................................................................................................. 9
Day 3 ....................................................................................................................................................................... 10
Colin Wright, .......................................................................................................................................................... 10
Niroshini Nirmalan .................................................................................................................................................. 10
Mohga Kamal-Yanni ................................................................................................................................................ 10
José M. Bautista ...................................................................................................................................................... 10
Frederick Addai ....................................................................................................................................................... 10
Discussion Sessions ................................................................................................................................................. 10
Session breaks .......................................................................................................................................................... 10
Lunch ...................................................................................................................................................................... 11
• All the chicken in our lunch buffet is Halal ............................................................................................................. 11
• We have a number of dishes that are gluten free ................................................................................................. 11
• We have a range of vegetarian dishes which are separated from the meat and fish dishes ................................ 11
Frequently asked questions about our events ......................................................................................................... 11
Is the delegate list available? ................................................................................................................................... 11
Can I have the speakers slides? ................................................................................................................................ 11
Can I have a notepad? ............................................................................................................................................. 11
How can I keep up to date with Euroscicon Events? .............................................................................................. 11
I don’t want my photograph on any Euroscicon promotional material ............................................................. 11
Is there WIFI? .......................................................................................................................................................... 11
Can I have a CPD certificate? .................................................................................................................................. 11
Program Outline

Day 1: Vector Control: Research, Economics and Policy

The WHO estimations on the burden of malaria do not fully reflect the availability of new tools to fight the diseases nor the multiplicity of parasitological, epidemiology and treatment research - as well as the new thinking on financing - that have been taken place in the last decade. In fact 219 million cases of malaria occur every year around the world and 660,000 people still die - mainly in children under the age of 5. Moreover, it is evident that current funding levels do not allow for full implementation of the newest and most effective interventions globally: The Roll Back Malaria Partnership estimates that an annual funding gap of about $2.8 billion will need to be filled in order to reduce its incidence by 75% and malaria deaths to zero by 2015. This session aims at understanding the scientific, economic and political implications behind the opportunities and hurdles to stop this killing disease and to achieve the Millennium Development Goals targets.

Session Chair: Miss Giulia Boselli, Global Health Specialist- Consultant, UK

Giulia Boselli is a passionate Global Health Specialist interested in improving the access to essential medicines. She has started working at the World Health Organization where she designed and implemented a cost effective analysis in Laos for the Neglected Tropical diseases Department. Over the last years she has been enhancing her knowledge on the issues concerning the opportunities and hurdles to making malaria drug available in low income countries, working at Medicines for Malaria Venture (MMV) and at Population Service International (PSI). During her last experience she supervised a research on the availability and affordability of antimalarial drugs in East Africa.

Day 2: Immunology and Vaccination

This session will discuss the mechanisms of immunity and immunopathology in order to facilitate vaccine design and the identification of additional therapies for treatment of severe malaria. There will be plenty of opportunities for debate and networking.

Session Chair: Irene Gramaglia received her Ph.D from King’s College London and is currently an Associate Professor at the La Jolla Institute for Infectious Disease in San Diego, California. Her research focuses on the mechanisms of cerebral malaria pathogenesis using the mouse model of malaria. Her findings that nitric oxide bioavailability is critical for cerebral malaria pathogenesis forms the basis for much of her research. Her current research extends into pathways that can be manipulated to restore bioavailable nitric oxide and delves into alternative mechanisms by which therapeutics can protect against severe malaria in addition to effects on nitric oxide bioavailability.

Day 3: Drug Development and Resistance Control

Chemotherapy is our sole weapon to fight malaria and yet resistance has arisen to all current antimalarial drugs. It is predicted that resistant parasites will develop to virtually any antimalarial drug so there is a great need for continuous discovery of new drugs against this ancient disease. This session will discuss the development of new treatments for malaria together with the use of current drugs to limit, insofar as it is possible, any further development of resistance. There will be plenty of opportunity for delegates to present their work and network in an informal atmosphere, with a lot of time given for discussion and debate.

Morning Session Chair: Dr Glenn McConkey, Univeristy of Leeds, UK

Glenn McConkey has been focused on drug discovery against malaria parasites for the last 25 years with major discoveries in resistance to current antimalarial drugs and mechanisms of drug action. He has identified numerous new, novel targets for malaria drugs some of which have resulted in novel drugs undergoing clinical testing. His current work uses genomics information to model parasite growth for enhancing identification of malaria drug targets.

Afternoon Session Chair: Catherine Mullié, obtained a PhD in Microbiology and a PharmD at the University of Lille, France, in 1999. After a post-doc year at the Faculté de Medicine in Amiens (Laboratoire d’Immunologie, INSERM-EMI 0351), she became assistant professor at the Faculté de Pharmacie in Amiens in 2000 and joined the LG-2A (Laboratoire de Glycochimie des Antimicrobiens et des Agroressources, FRE-CNRS 3517) in 2008, in the team headed by Pr. Sonnet. The team current research is focused on the development of new antimicrobial and antimalarial drugs, with a special interest in the synthesis and biological evaluation of molecules bearing asymmetric carbons.
## Agenda (Talk times include 5 – 10 minutes for questions)

**Day 1: 1st July 2014**

### Vector Control: Research, Economics and Policy

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:30 – 10:15</td>
<td>Exhibitions open</td>
<td>Registration and Refreshments</td>
</tr>
<tr>
<td>10:15 – 10:30</td>
<td>Introduction by the Chair</td>
<td>Miss Giulia Boselli, Global Health Specialist-Consultant, UK</td>
</tr>
<tr>
<td>10:30 – 11:10</td>
<td>Possible new controlling measures for the pyrethroid-resistant malaria vectors</td>
<td>Dr Hitoshi Kawada, Associate Professor, Institute of Tropical Medicine, Nagasaki University, Japan</td>
</tr>
<tr>
<td>11:10 – 11:50</td>
<td>Malaria control in coastal areas - special research and policy needs</td>
<td>Professor Ranjan Ramasamy, Visiting Professor, University of Jaffna, Sri Lanka</td>
</tr>
<tr>
<td>11:50 – 12:20</td>
<td>Session Break</td>
<td>Speakers’ photo, Refreshments and Poster viewing</td>
</tr>
<tr>
<td>12:20 – 12:40</td>
<td>ORAL PRESENTATION</td>
<td><strong>MALE FERTILITY FOLLOWING OCCUPATIONAL EXPOSURE TO DDT.</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>P. Cocco, M. Campagna, D. Fadda, G. Satta, Department of Public Health, Clinical and Molecular Medicine, Occupational Health Section, University of Cagliari, Asse Didattico E, SS 554, km 4,500, 09042 Monserrato (Cagliari), Italy. Tel: +390705754711; Fax: +390705754728; e-mail: <a href="mailto:cocopp@medicina.unica.it">cocopp@medicina.unica.it</a></td>
</tr>
<tr>
<td>12:40 – 13:20</td>
<td>Enantioselective pharmacologic and toxicologic profiles of 8-aminoquinoline antimalarials</td>
<td><strong>Professor Babu Tekwani, University of Mississippi, USA</strong></td>
</tr>
<tr>
<td>13:20 - 14:20</td>
<td>Session Break</td>
<td>Lunch and Poster viewing</td>
</tr>
<tr>
<td>14:20 -15:00</td>
<td>Discussion session</td>
<td></td>
</tr>
<tr>
<td>15:00 – 15:30</td>
<td>Session Break</td>
<td>Refreshments and Last poster viewing</td>
</tr>
<tr>
<td>15:30 – 16:10</td>
<td>ORAL PRESENTATION</td>
<td><strong>THE ‘PADDY PARADOX’ REVISITED: HOW RICE FARMING IMPACTS ON HOUSEHOLD ECONOMIC STATUS AND MALARIA RISK IN EASTERN RWANDA</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Rulisa, F. Kaatera, C. Ingabire, E. Hakizimana, M.Vugt, L. Mutesa, L.Kempen, P.O. Box 6655 Kigali, Rwanda</td>
</tr>
<tr>
<td>15:50 – 16:10</td>
<td>MATHEMATICAL MODEL FOR THE SPREAD OF PYRIMETHAMINE RESISTANCE IN PLASMODIUM FALCIPARUM</td>
<td>Mario Cañón Ayala*, Hernando Díaz*, Vladimir Corredor Espinel** and Andrés Olarte*</td>
</tr>
<tr>
<td></td>
<td></td>
<td>*Departamento de Ingeniería Eléctrica y Electrónica, Facultad de Ingeniería. **Departamento de Salud pública, Facultad de Medicina. Universidad Nacional de Colombia. Bogotá, Colombia. <a href="mailto:mjcanona@unal.edu.co">mjcanona@unal.edu.co</a>, <a href="mailto:hdlazmo@unal.edu.co">hdlazmo@unal.edu.co</a>, <a href="mailto:vcorredore@unal.edu.co">vcorredore@unal.edu.co</a> and <a href="mailto:faolarted@unal.edu.co">faolarted@unal.edu.co</a></td>
</tr>
<tr>
<td>16:10 – 16:50</td>
<td>Education in the successful elimination of malaria in Palestine begun 90 years ago</td>
<td>Mr Anton Alexander LL.B, London, UK</td>
</tr>
<tr>
<td>16:50 - 17:00</td>
<td>Chairman’s Summing Up</td>
<td>Close of Session</td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
<td>Speaker/Institution</td>
</tr>
<tr>
<td>--------------</td>
<td>---------------------------------------------------------------------------------------------</td>
<td>-----------------------------------------------------------</td>
</tr>
<tr>
<td>09:30 – 10:15</td>
<td>Exhibitions open</td>
<td>Registration and Refreshments</td>
</tr>
<tr>
<td>10:15 – 11:00</td>
<td>Introduction by the Chair</td>
<td>Dr Irene Gramaglia, Associate Professor, La Jolla Infectious Disease Institute, USA</td>
</tr>
<tr>
<td></td>
<td>Citrulline: A novel therapeutic for the cerebral malaria</td>
<td></td>
</tr>
<tr>
<td>11:00 – 11:30</td>
<td>Prospects for Preganancy-Associated Malaria Vaccination Predicated on Antibody-Mediated Immunity</td>
<td>Professor Andrew Taylor-Robinson, Professor of Immunology/Haematology &amp; Deputy Dean Research</td>
</tr>
<tr>
<td>11:30 – 12:00</td>
<td>Session Break</td>
<td>Speakers' photo, Refreshments and Poster viewing</td>
</tr>
<tr>
<td>12:00 – 12:30</td>
<td>Etiology and treatment of cerebral malaria</td>
<td>Jacob Golenser, Kuvin, Centre for the Study of Infectious and Tropical Diseases, The Hebrew University of Jerusalem-Hadassah Medical School, Israel</td>
</tr>
<tr>
<td>12:30–13:00</td>
<td>Dendritic cells during malaria infection</td>
<td>Dr Pierre Guermonprez, Center for Molecular and Cellular Biology of Inflammation, King's College London, United Kingdom</td>
</tr>
<tr>
<td>13:00 – 14:00</td>
<td>Session Break</td>
<td>Lunch and Poster viewing</td>
</tr>
<tr>
<td>14:00 – 15:00</td>
<td>Discussion session</td>
<td></td>
</tr>
<tr>
<td>15:00 – 15:30</td>
<td>Session Break</td>
<td>Refreshments, Last poster viewing, Last Sponsors exhibition</td>
</tr>
<tr>
<td>15:30 – 16:00</td>
<td>Antibody longevity to malaria vaccine candidate antigens in immuno-epidemiology studies</td>
<td>Dr Freya Fowkes, Head of Malaria and Infectious Disease Epidemiology, Burnet Institute, Australia</td>
</tr>
<tr>
<td>16:00 – 16:30</td>
<td>Platelets do not kill blood-stage Plasmodium parasites but function in experimental cerebral malaria pathogenesis.</td>
<td>Dr Joyce M. Velez, Post-doctoral fellow, La Jolla Infectious Disease Institute, USA</td>
</tr>
<tr>
<td>16:30</td>
<td>Chairman's Summing Up</td>
<td>Close of Session</td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
<td>Speaker/Details</td>
</tr>
<tr>
<td>--------------</td>
<td>----------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>9:30 – 10:15</td>
<td>Exhibitions open</td>
<td>_registration and refreshments</td>
</tr>
<tr>
<td>10:15 – 11:00</td>
<td>Introduction by session Chair Malaria Drug Discovery: From genome to drug lead</td>
<td>Dr. Glenn McConkey, University of Leeds, UK</td>
</tr>
<tr>
<td>11:00 – 11:30</td>
<td>Natural products as a source of new drugs and/or herbal treatments for malaria</td>
<td>Dr Colin Wright, Reader in Pharmacognosy, Bradford School of Pharmacy, University of Bradford, UK</td>
</tr>
<tr>
<td>11:30 – 11:50</td>
<td>Session Break</td>
<td>Speakers’ photo, refreshments and poster viewing</td>
</tr>
<tr>
<td>11:50 – 12:20</td>
<td>Fast tracking antimalarial drug discovery through repositioning</td>
<td>Nirmalan Niroshini, University of Salford, Manchester, UK</td>
</tr>
<tr>
<td>12:20 – 12:50</td>
<td>ORAL PRESENTATIONS</td>
<td></td>
</tr>
<tr>
<td></td>
<td>TRES CANTOS OPEN LAB: CATALYZING INNOVATION IN DISEASES OF THE DEVELOPING WORLD DRUG DISCOVERY</td>
<td>Elena Fernández-Alvaro and Luís Balliet-Pages, GlaxoSmithKline. Diseases of the Developing World-Tres Cantos Medicines Development Campus. Tres Cantos 28760, Madrid, Spain</td>
</tr>
<tr>
<td>12:40 – 12:50</td>
<td>Khaya grandifoliola: POTENTIAL SOURCE OF ANTI-MALARIAL DRUG</td>
<td>J. M. Agbedahunsi PhD, Drug Research and Production Unit, Faculty of Pharmacy, Obafemi Awolowo University, Ile Ife, Nigeria</td>
</tr>
<tr>
<td>12:50 – 13:40</td>
<td>Session Break</td>
<td>Lunch and poster viewing</td>
</tr>
<tr>
<td>13:40 – 14:20</td>
<td>Introduction by session Chair Development of enantiomerically pure aminoalcohol quinoline derivatives to improve their antimalarial efficiency and assessment of their activity against Plasmodium falciparum in combination with dihydroartemisinin</td>
<td>Dr. Catherine Mullié, Faculté de Pharmacie, Université de Picardie Jules Verne, France</td>
</tr>
<tr>
<td>14:20 – 14:40</td>
<td>Artemether Loaded Nanoparticles: Development using Quality by Design approach, evaluation of antimalarial efficacy and uptake specifically by malaria-infected erythrocytes</td>
<td>Professor Kamalinder K Singh, School of Pharmacy and Biomedical Sciences, University of Central Lancashire, Preston, United Kingdom</td>
</tr>
<tr>
<td>14:40 – 15:10</td>
<td>ORAL PRESENTATIONS</td>
<td></td>
</tr>
<tr>
<td>14:40 – 14:50</td>
<td>A ROLE FOR AMP DEAMINASE IN MALARIA RESISTANCE</td>
<td>E. Hrtle, B. Nijagal, D. Bauer, S. Lampkin, M. McConville, B. McMorrain, G. Burgio, S. Foote, Australian School of Advanced Medicine, 2 Technology Place, Macquarie University NSW 2109, Australia</td>
</tr>
<tr>
<td>14:50 – 15:00</td>
<td>ROLE OF HOST IMMUNE SYSTEM IN THE CLEARANCE OF RODENT PLASMODIUM DURING ARTESUNATE MONOTHERAPY</td>
<td>Carla Cisneros, Zi Wei Chang, Hutt Wang Teo, Laurent Renia, Singapore Immunology Network (SlN), Agency for Science, Technology and Research (ASTAR), 8A Biomedical Grove, Immunos Building, Level 3, Biopolis, Singapore</td>
</tr>
<tr>
<td>15:00 – 15:10</td>
<td>A RAPID IN VITRO BIOLUMINESCENCE-BASED RATE-OF-KILL (BRoK) ASSAY TO SCREEN THE MMV “MALARIA BOX”</td>
<td>Imran Ullah, Rhianann Blow and Paul Horrocks, Institute for Science and Technology in Medicine, Keele University, Staffordshire ST5 5BG</td>
</tr>
<tr>
<td>15:10 – 15:30</td>
<td>Antimalarials that improve the immune response</td>
<td>Professor José M. Bautista, Complutense University of Madrid, Madrid, Spain</td>
</tr>
<tr>
<td>15:30 – 15:40</td>
<td>Session Break</td>
<td>refreshments and last poster viewing</td>
</tr>
<tr>
<td>15:40 – 16:00</td>
<td>NEW ANTIMALARIAL DRUG LEADS AND MOLECULAR TARGETS IDENTIFIED THROUGH MULTIDIRECTIONAL SCREENING AND DRUG DISCOVERY APPROACH</td>
<td>Babu L. Tekwani, Rajnish Sahu, Jagrati Jain, Shabana I Khan, Muhammad Illass, Mark T Hamman, Mitchell A Avery, Waseem Gul, Mahmoud A. Elsohly, NP Dhammika Nanayakkara, Stephen O. Duke and Larry A Walker, National Center for Natural Products Research, Department of Pharmacology, Pharmacognosy and Medicinal Chemistry, School of Pharmacy, University of Mississippi, University MS 38677, USA; Elsohly Laboratories Inc, Oxford 38655 MS USA; USDA-ARS, Natural Products Utilization Research, University, MS 38677, USA</td>
</tr>
<tr>
<td>16:00 – 16:30</td>
<td>Malaria control: the nutraceutical potential of natural cocoa powder</td>
<td>Professor Frederick Addai, Academic Researcher, University of Ghana Medical School, Ghana</td>
</tr>
<tr>
<td>16:30 – 17:00</td>
<td>Treating malaria at the expense of public health?</td>
<td>Dr. Mohga Kamal-Yanni, Senior health &amp; HIV policy advisor, Oxfam UK</td>
</tr>
<tr>
<td>17:00</td>
<td>Chairman’s Summing Up</td>
<td>Close of Meeting</td>
</tr>
</tbody>
</table>
About the Speakers

Day 1

Hitoshi Kawada, has ca 20 years experience as a developing manager in the chemical company before he took a present position 10 years ago. His background is medical entomology and pesticide biology. His main interests are behavior of vector mosquitoes, development of new insecticide devices for control of vector mosquitoes, and insecticide resistance.

Ranjan Ramasamy, obtained a BA and PhD from the University of Cambridge. He worked on the immunobiology of lymphocyte membranes in the UK and later on the immunobiology of blood-borne parasites and malaria vaccines in Africa, Asia, Australia and the USA. Collaborative work with entomologists, including his wife, also led to significant discoveries on the biology of mosquito vectors of malaria and arboviral diseases. He was a Professor of Biochemistry and Immunology, the Chairman of the National Science Foundation of Sri Lanka, and a Visiting Fellow at St. Edmund’s College Cambridge. He also served on several international scientific bodies

Anton Alexander, LL.B, London, UK
Retired lawyer researching the history of Malaria elimination in Palestine

Day 2

Andrew Taylor-Robinson, Professor of Immunology/Haematology & Deputy Dean Research | School of Medical & Applied Sciences, CQ University Rockhampton, Queensland, Australia
He gained a PhD in parasite immunology from the University of Glasgow for work on immunity to malaria. Following postdoctoral posts at Edinburgh and Glasgow, he moved to Leeds as a Welcome Trust Career Development Research Fellow, subsequently appointed to the academic staff. He has over 25 years' research experience of infectious disease immunology, with focus on malaria, dengue and other vector-borne diseases. His interests include understanding regulation of the immune response, effector mechanisms of protective immunity and their potentiation for vaccine design.

Jacob Golenser, is attempting to define and validate new drug targets, produce derivatives of existing drugs, and use combinations of anti-parasitic drugs that might be synergistic or prevent the development of resistance. Parasitic infections may be overcome by balanced immune responses. Drugs may affect the disease by reducing parasite load and by altering the immune responses. Therefore, JG is investigating drug effects on both parasites and immune functions. The variety of techniques which have been used throughout JG's research with parasites are also applied in experiments concerning other human diseases. JG is affiliated in the Hebrew University of Jerusalem and spent long periods in field studies in Africa and research periods in Europe, USA and recently in the University of Sydney, Australia.

Pierre Guermonprez, Center for Molecular and Cellular Biology of Inflammation, King's College London, United Kingdom
Pierre Guermonprez, obtained is PhD at the Pasteur Institute in Paris with Pfr C. Leclerc. After post-doctoral training with Pfr Amigorena (Curie Institute, Paris) and Pfr Nussenzweig (Rockefeller University, New York), P. Guermonprez joined King’s College London in 2012 where he focus his research on the immunobiology of dendritic cells.

An NHMRC Public Health Fellow, Freya Fowkes is Head of the Malaria and Infectious Disease Epidemiology group at the Burnet Institute. Freya is involved primarily in examining the epidemiology of malaria in particular analysing malaria immunological data from large population-based studies. She completed her doctorate in 2007 at the University of Oxford and has held research associate positions at the New York University School of Medicine and the Walter and Eliza Hall Institute. Currently, Freya holds an adjunct senior research fellow position at Monash University and is an honorary fellow of the University of Melbourne.

Joyce M. Velez, completed her bachelor's degree in biology at University of Puerto Rico in San Juan, PR. She then received a PhD in Toxicology at University of Kentucky in Lexington, KY. As a postdoctoral fellow she received training in the areas of neuroendocrinology, neurotoxicology, and neuroAIDS at the Medical Sciences Campus of the University of Puerto Rico. She is currently a Postdoctoral researcher at the Malaria Research Center in La Jolla Infectious Disease Institute in San Diego, CA.
Day 3

Colin Wright, studied pharmacy at the School of Pharmacy, University of London, and worked in hospital and community pharmacy before returning to carry out research on antimalarial and anti amoebic natural products, obtaining his Ph.D in 1989. He has continued his research at Bradford School of Pharmacy since 1994 particularly on the theme of antimalarial drug development from natural products.

Niroshini Nirmalan, obtained her PhD in 1999 and completed her post-doctoral training in Prof John Hyde’s laboratory at UMIST. She was Senior Research Fellow at the Manchester Interdisciplinary Biocenter, University of Manchester where her work lead to the development of a novel isoleucine-based quantitative proteomic methodology to investigate the malarial proteome. She was appointed Senior Scientist at the CRUK Clinical Center, St James’s Hospital, Leeds in 2007 where she worked on label-free quantitative proteomics methodologies to investigate formalin-fixed tissue archives. She took up her current role as Senior Lecturer at the University of Salford in April 2010.

Mohga Kamal-Yanni, Senior health & HIV policy advisor, Oxfam UK

José M. Bautista, obtained his Ph.D. in 1987, completed postdoctoral training at the University of London-Royal Postgraduate Medical School, and joined the faculty of Complutense University of Madrid as an Assistant Professor in 1991. He has been visiting scientist at Imperial College of Medicine –Hammersmith Hospital (London), Institute of Genetics and Biophysics (Naples), University for Developmental Studies (Tamale-Ghana) and Cheikh Anta Diop University (Dakar-Senegal). Full Professor since 2007 at present direct the Department of Biochemistry and Molecular Biology IV at Complutense University of Madrid and the research group Translational Haematology II at the Research Institute Hospital 12 de Octubre in Madrid. Dr. Bautista's research is on improving preclinical models of malaria and highthroughput proteomic methods to determine long term effect of antimalarials including immune response.

Frederick Addai, is an Associate Professor, whose 10-year research in 2004 affirmed healthful gains of consuming good cocoa products. He has supervised ten graduate studies on health benefits of cocoa, and spawned many more independent studies. Personal and community anecdotal experiences with daily consumption of cocoa as unsweetened beverage, provoked research that confirms antimalarial activity of natural cocoa. He has given numerous print and electronic media presentations locally and internationally; including invited talks at the 15th International Cocoa Research Conference (ICRC) in Costa Rica, and 69th General Assembly and Council of Ministers Meeting of the Cocoa Producers’ Alliance (COPAL), Abidjan, La Cote d’Ivoire.

Discussion Sessions
The discussion sessions are an opportunity for informal questions and answers. This is an ideal opportunity to get advice and opinion from experts in this area. This session is not for questions about specific talks, which can be asked after the speakers session, but for discussing either general topics or specific issues.

There are three ways you can ask questions:

1. Before the session you can submit your question to Euroscicon staff at the registration desk,
2. Before and during the session you can submit a question or comments, by email, which will be provided on the day of the event
3. During the session you can put your hand up and join in

Session breaks
All breaks and registrations will take place in the exhibition area where there will be lunch and refreshments.

Please try to visit all the exhibition stands during this event. Not only do our sponsors enable Euroscicon to keep the registration fees competitive, but they are also here specifically to talk to you
Lunch

- All the chicken in our lunch buffet is Halal
- We have a number of dishes that are gluten free
- We have a range of vegetarian dishes which are separated from the meat and fish dishes

Frequently asked questions about our events

Is the delegate list available?
Yes this is available to everyone who attends the event and our sponsors. It is available in real time. To access the list please just log into your registration details or use the QR code on right of the agenda card which is provided on the day of the event.
You will not be included in this list if you have opted out and you can do this by logging into your registration details. This list will not be sold or ever give out to third parties.

Can I have the speakers slides?
We cannot give out the slides from our speaker’s presentations as they are deleted immediately after each event. If you require a particular set of slides please approach the speaker. We will however have a meeting report and you will be emailed when this report is published.

Can I have a notepad?
Notepads and pens are provided in the delegate bags and at the registration desk

How can I keep up to date with Euroscicon Events?
To keep updated on our events and other Life Science News, please sign up for our newsletter at www.eurosciconnews.com

I don’t want my photograph on any Euroscicon promotional material
Please let our tech person know

Is there WIFI?
Yes, please ask registration for log in details

Can I have a CPD certificate?
CPD certificates will be available in the exhibition hall after lunch

Please remember that EuroSciCon is a small independent company with no subsidies from society memberships or academic rates for venues. We try to be as reasonably priced as possible and our delegate rates are substantially lower than comparable commercial meeting organisations